Business Context and Reporting Period
This Form 8-K is a current report filed by Neuralstem, Inc. (not Palisade Bio, Inc.) on April 24, 2007. The filing reports corporate governance changes, specifically the appointment of two new directors to the Board of Directors effective April 12, 2007, and the adoption of a new director compensation plan.
Key Financial Metrics
This filing does not contain financial performance data. There are no reported figures for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on personnel appointments and equity-based compensation structures.
Material Changes
- Board Expansion: The Board of Directors increased the number of director positions from two to four.
- New Appointments: Scott V. Ogilvie and William C. Oldaker were appointed to fill the vacant positions. Both will serve until the next annual shareholders meeting.
- Compensation Plan: A new director compensation plan was adopted, granting stock options based on tenure and committee service.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding business operations. The primary risk disclosed relates to the dilution of existing shareholders due to the issuance of stock options to new directors. The filing notes that the exercise price for these options will be the market price of the stock on the applicable grant date.
Director Compensation Details
- Initial Grant: 20,000 shares upon joining (10,000 vest in one month; 10,000 vest quarterly over one year).
- Annual Grant: 10,000 shares per year anniversary, vesting quarterly.
- Committee Grant: 5,000 shares for each committee served, vesting quarterly.
Investor Verification Checklist
- Verify the current share count and potential dilution impact from the 20,000 initial options granted to each new director.
- Confirm the market price of Neuralstem, Inc. stock on the grant date to determine the exercise price of the options.
- Review the biographies of Scott V. Ogilvie and William C. Oldaker to assess their specific expertise relative to the company's biotechnology focus.
- Check subsequent filings to confirm if the directors were elected at the next annual shareholders meeting.